Innate Immunotherapeutics (ASX:IIL)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Innate Immunotherapeutics.
RELATED STOCKHEAD STORIES
Ex-Innate director charged with insider trading in the US
Lunchtime small cap wrap: who’s racing ahead and who’s falling behind
What’s next for Innate Immuno after Plan B sends shares up 300pc
Innate switches to cancer after failed MS bid, shares rocket 187pc
